Subscribe to get the latest news and updates.
Headquartered in Ahmedabad, India, the group ranks 4th in the Indian pharmaceutical industry with manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim. Globally, the group has a strong presence in the regulated markets of the US, Europe (France & Spain) and the high profile markets of Latin America and South Africa. It also has a strong presence in 25 other emerging markets worldwide.
The India Business comprises the India formulations business spearheaded by Zydus Healthcare Ltd., based in Mumbai and the Biologics business which drives the sales and marketing of biosimilars and novel biologics.
Zydus is one of the oldest players in the Indian formulations market and has gone onto become a prominent pharmaceutical manufacturer in India. Besides continuously improving its market presence and market share, the group has also expanded its portfolio by entering newer therapeutic areas.The group has been launching new products with the first mover advantage and has a strong presence in both acute and chronic therapies.
These strategic initiatives have helped Zydus become one of the dominant players in the Indian formulations market with the leadership position in several therapeutic categories.The group’s innovative NCE therapy Lipaglyn, a novel drug to be approved for the treatment of diabetic dyslipidemia is marketed by Zydus Discovery, a division of Zydus Healthcare Ltd.
Zydus Biologics, a super-specialty centric business entity of Zydus Lifesciences Ltd., is engaged in manufacturing and commercialization of both, small molecule, biological drugs and vaccines intended for prevention and treatment of various diseases in the field of oncology, hepatology, nephrology, rheumatology, ophthalmology and bone health. With capabilities across the value chain - Drug development, manufacturing, distribution and commercialization, Zydus Biologics has emerged as one of the leading players in the biologics market and has a formidable presence in its participatory market. Zydus Biologics' developmental capabilities cover fusion proteins, monoclonal antibodies, antibody drug conjugates and vaccines. It has a robust pipeline comprising of next generation biosimilars, and novel biologicals.
As part of its vision of being at the forefront of innovation led growth, Zydus Biologics has undertaken several pioneering initiatives like launching Exemptia, world's first biosimilar of Adalimumab, Vaxiflu S - Indian's first indigenously developed H1N1 vaccine for protection against swine flu, Vaxiflu 4 - India's first quadrivalent influenza vaccine and ZyVac TCV – World’s second brand of typhoid conjugate vaccine.
In line with the group’s endeavour to improve access to healthcare for the public at large, Zydus Biologics has initiated various developmental programmes in the vaccines and diagnostics space. The aim is to cater to unmet needs of the people of this country in the field of immunization and detection of rare infectious diseases.
The group has manufacturing capabilities across the value chain including formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products as well as wellness products with more than 30 manufacturing plants worldwide including India, Germany, Brazil & USA
Finished Dosage Form, Moraiya, Ahmedabad
Finished Dosage Form, Baddi
Finished Dosage Form, Goa
Formulations Plant at Sikkim
Biologics Active Substances, Zydus Biologics, Ahmedabad
Alidac Pharmaceuticals Ltd., Pharmez, Ahmedabad
Cytotoxic Injectable JV with Pfizer
Transdermals Manufacturing Zydus Technologies Limited, Pharmez, Ahmedabad
Topical Formulation Manufacturing, Pharmez, Ahmedabad
Finished Dosage Form, Brazil
Liquid & Solid Oral Dosage Products, Nesher Pharma, USA
Plasmid DNA Vaccine Manufacturing, Ahmedabad
Matoda SEZ Plant, Matoda
Zydus is fully committed to and continuously endeavors to achieve environment, health and safety excellence across all the units. The Company continues to invest substantial resources towards sustaining and continuously improving the standards of environment, occupational health and safety as it believes that its responsibility towards the society and the environment extends beyond those laid down by the regulatory authorities.EHS Policy